Silence Therapeutics (SLN) Cost of Revenue (2024 - 2026)

Silence Therapeutics has disclosed Cost of Revenue across 3 years of filings, most recently posting $11000.0 for Q1 2026.

• Cost of Revenue for Q1 2026 came in at $11000.0, down 79.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $172000.0 (down 98.1% YoY), and the FY2025 annual result was $215000.0, down 98.18% from the prior year.
• Cost of Revenue came in at $11000.0 for Q1 2026 at Silence Therapeutics, down from $12000.0 in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $3.6 million in Q3 2024 to a low of $11000.0 in Q1 2026.
• The 3-year median for Cost of Revenue is $85000.0 (2025), against an average of $1.3 million.
• Across the five-year window, Cost of Revenue plunged 99.41% in 2025 and slumped 79.63% in 2026, its largest moves.
• Silence Therapeutics' Cost of Revenue stood at $2.0 million in 2024, then slumped by 99.41% to $12000.0 in 2025, then dropped by 8.33% to $11000.0 in 2026.
• The last three Cost of Revenue figures came in at $11000.0 (Q1 2026), $12000.0 (Q4 2025), and $64000.0 (Q3 2025), per Business Quant data.